131 related articles for article (PubMed ID: 6414691)
41. Irreversible encephalopathy with ifosfamide/mesna.
Salloum E; Flamant F; Ghosn M; Taleb N; Akatchereian C
J Clin Oncol; 1987 Aug; 5(8):1303-4. PubMed ID: 3114437
[No Abstract] [Full Text] [Related]
42. [Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan].
Czownicki Z; Utracka-Hutka B
Nowotwory; 1981; 30(4):377-83. PubMed ID: 6792599
[No Abstract] [Full Text] [Related]
43. Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.
Araujo CE; Tessler J
Eur J Cancer Clin Oncol; 1983 Feb; 19(2):195-201. PubMed ID: 6402369
[TBL] [Abstract][Full Text] [Related]
44. Bioavailability of orally administered mesna.
Burkert H; Lücker PW; Wetzelsberger N; Breuel HP
Arzneimittelforschung; 1984; 34(11):1597-600. PubMed ID: 6441581
[TBL] [Abstract][Full Text] [Related]
45. Avoiding ifosfamide/mesna encephalopathy.
Meanwell CA; Kelly KA; Blackledge G
Lancet; 1986 Aug; 2(8503):406. PubMed ID: 2874408
[No Abstract] [Full Text] [Related]
46. A phase I study of prolonged ambulatory infusion of Ifosfamide with oral mesna.
Olver I; Keefe D; Myers M; Caruso D
Chemotherapy; 2005 May; 51(2-3):142-6. PubMed ID: 15886474
[TBL] [Abstract][Full Text] [Related]
47. Ifosfamide/mesna encephalopathy.
McCallum AK
Lancet; 1987 Apr; 1(8539):987. PubMed ID: 2882385
[No Abstract] [Full Text] [Related]
48. Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector.
Falkson CI; Falkson HC; Falkson G
Invest New Drugs; 1989 Jul; 7(2-3):261-7. PubMed ID: 2507474
[TBL] [Abstract][Full Text] [Related]
49. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
Andriole GL; Sandlund JT; Miser JS; Arasi V; Linehan M; Magrath IT
J Clin Oncol; 1987 May; 5(5):799-803. PubMed ID: 3106585
[TBL] [Abstract][Full Text] [Related]
50. Encephalopathy associated with ifosphamide/mesna therapy.
Meanwell CA; Blake AE; Latief TN; Blackledge G; Mould JJ; Blake DR; Shaw IC; Honigsberger L; Spooner D; Williams AC
Lancet; 1985 Feb; 1(8425):406-7. PubMed ID: 2857462
[No Abstract] [Full Text] [Related]
51. [Prevention of urotoxic actions of cyclophosphamide and ifosfamide by dimesna (preliminary communication) (author's transl)].
Brock N; Stekar J
Arzneimittelforschung; 1982; 32(5):486-7. PubMed ID: 6809014
[TBL] [Abstract][Full Text] [Related]
52. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma.
Antman KH; Ryan L; Elias A; Sherman D; Grier HE
J Clin Oncol; 1989 Jan; 7(1):126-31. PubMed ID: 2491883
[TBL] [Abstract][Full Text] [Related]
53. Treatment of metastatic renal cancer with ifosfamide and mesnum with and without irradiation.
Fosså SD; Talle K
Cancer Treat Rep; 1980; 64(10-11):1103-8. PubMed ID: 6780190
[TBL] [Abstract][Full Text] [Related]
54. Ifosfamide continuous infusion without mesna. A phase I trial of a 14-day cycle.
Lokich I; Anderson N; Bern M; Moore C
Cancer; 1991 Feb; 67(4):883-5. PubMed ID: 1899352
[TBL] [Abstract][Full Text] [Related]
55. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.
Dechant KL; Brogden RN; Pilkington T; Faulds D
Drugs; 1991 Sep; 42(3):428-67. PubMed ID: 1720382
[TBL] [Abstract][Full Text] [Related]
56. Cyclophosphamide and ifosfamide: role of uroprotective agents.
Williams SD; Munshi N; Einhorn LH; Loehrer PJ
Cancer Invest; 1990; 8(2):269. PubMed ID: 2119246
[No Abstract] [Full Text] [Related]
57. [Antidote against the urotoxic effects of the oxazaphorine derivatives cyclophosphamide, ifosfamide and trofosfamide].
Brock N; Stekar J; Pohl J
Naturwissenschaften; 1979 Jan; 66(1):60-1. PubMed ID: 106307
[No Abstract] [Full Text] [Related]
58. Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas.
Ajani JA; Abbruzzese JL; Goudeau P; Faintuch JS; Yeomans AC; Boman BM; Nicaise C; Levin B
J Clin Oncol; 1988 Nov; 6(11):1703-7. PubMed ID: 3141592
[TBL] [Abstract][Full Text] [Related]
59. Phase II trial of ifosfamide/mesna in metastatic adult renal carcinoma.
De Forges A; Droz JP; Ghosn M; Theodore C
Cancer Treat Rep; 1987 Nov; 71(11):1103. PubMed ID: 3119203
[No Abstract] [Full Text] [Related]
60. Ifosfamide given as a 24-h infusion with mesna in patients with recurrent ovarian cancer: preliminary results.
Willemse PH; vd Burg ME; vd Gaast A; Neijt JP; ten Bokkel Huinink WW; Aalders JG; de Vries EG
Cancer Chemother Pharmacol; 1990; 26 Suppl():S51-4. PubMed ID: 2112053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
